ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

mirikizumab

Also written as “Mirikizumab”, “LY3074828” and “Mirikizumab IV”.

Its studies are mostly in Colitis, Ulcerative · Psoriasis · Crohn Disease · Breast Feeding, led by 2 companies.

Drug pageMirikizumab: every studyAll 44 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since May 21, 202636 company-led studies, 7 open or runningNext primary completion: Feb 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Eli Lilly356 open or runningphase 4since May 21, 2026Sep 18, 2013Feb 2027phase 1 · NCT07446101
Rubix LSits history only11 open or runningphase 4since Jul 1, 2025Jul 1, 2025none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Eli Lilly only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

Not listed one by one: 21 earlier studies, Sep 18, 2013 to Oct 22, 2019.

  1. Jun 9, 2017Named mirikizumabINNProposed as its International Nonproprietary Name in WHO's List 117 · before, LY3074828
  2. Jan 15, 2020Phase 3 study in Crohn DiseaseNCT04232553 · 996 enrolled · United States, Argentina, Australia and more
  3. Jul 10, 2020Phase 3 study in Colitis, UlcerativeNCT04469062
  4. Sep 10, 2020Phase 1 study in HealthyNCT04548219 · 60 enrolled · United States
  5. Oct 28, 2020Phase 1 study in HealthyNCT04607733 · 240 enrolled · United States
  6. Apr 12, 2021Phase 3 study in Colitis, UlcerativeNCT04844606 · 150 planned · United States, Austria, Belgium and more
  7. Oct 1, 2021Phase 1 study in HealthyNCT05069896 · 237 enrolled · United States
  8. Aug 19, 2022Phase 3 study in Crohn DiseaseNCT05509777 · 90 planned · United States, Austria, Belgium and more
  9. Aug 24, 2022Phase 1 study in HealthyNCT05515601 · 396 enrolled · United States
  10. Dec 1, 2022Phase 1 study in HealthyNCT05644353 · 450 enrolled · United States
  11. Feb 8, 2023Phase 3 study in Colitis, UlcerativeNCT05767021 · 172 enrolled · United States, Belgium, Czechia and more
  12. Mar 13, 2023Phase 3 study in Colitis, UlcerativeNCT05784246 · 63 enrolled · United States, Belgium, Canada and more
  13. Jun 21, 2024Phase 1 study in HealthyNCT06475729 · 498 enrolled · United States
  14. Feb 26, 2026Phase 1 study in HealthyNCT07446101 · 450 planned · United States
  15. May 21, 2026Phase 4 study in Breast FeedingNCT07612267 · 14 planned · United States, Canada, Denmark and more

Ahead

  1. Feb 2027Primary completion: phase 1 study in HealthyNCT07446101
  2. Dec 2027Primary completion: phase 3 study in Crohn DiseaseNCT05509777
  3. Sep 2028Primary completion: phase 4 study in Breast FeedingNCT07612267
  4. Dec 2030Primary completion: phase 3 study in Colitis, UlcerativeNCT04844606

TargetBeta

IL12B →IL23A →read by rule
“Interleukin-23 inhibitor”ChEMBL 37, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
risankizumabruleAbbViephase 468
guselkumabruleJohnson & Johnsonphase 460

Studies

All 35 Eli Lilly leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07612267Breast Feeding · United States, Canada, Denmark and more4RecruitingSep 202814
NCT07446101Healthy · United States1RecruitingFeb 2027450
NCT06475729Healthy · United States1CompletedDec 27, 2024498
NCT05784246Colitis, Ulcerative · United States, Belgium, Canada and more3CompletedMay 1, 202663
NCT05767021Colitis, Ulcerative · United States, Belgium, Czechia and more3CompletedAug 9, 2024172
NCT05644353Healthy · United States1CompletedMay 25, 2023450
NCT05515601Healthy · United States1CompletedFeb 20, 2023396
NCT05509777Crohn Disease · United States, Austria, Belgium and more3RecruitingDec 202790
NCT05069896Healthy · United States1CompletedJun 22, 2022237
NCT04844606Colitis, Ulcerative · United States, Austria, Belgium and more3RecruitingDec 2030150
NCT04607733Healthy · United States1CompletedMay 17, 2021240
NCT04548219Healthy · United States1CompletedJan 11, 202160
NCT04469062Colitis, Ulcerative3WithdrawnMar 13, 20240
NCT04232553Crohn Disease · United States, Argentina, Australia and more3Active, not recruitingNov 28, 2024996
NCT04137380Healthy · China1CompletedDec 11, 202060
NCT04004611Colitis, Ulcerative · United States, Canada, Israel and more2CompletedMar 15, 202326
NCT03926130Crohn Disease · United States, Argentina, Australia and more3CompletedAug 23, 20231,158
NCT03718884Psoriasis · United States1CompletedOct 28, 201929
NCT03748940Healthy · United Kingdom1CompletedJun 18, 201960
NCT03662100Healthy · United States1CompletedJan 25, 201966
NCT03556202Psoriasis · United States, Argentina, Australia and more3TerminatedFeb 7, 20221,936
NCT03535194Psoriasis · United States, Argentina, Australia and more3CompletedMar 5, 20201,484
NCT03524092Colitis, Ulcerative · United States, Argentina, Australia and more3CompletedNov 3, 20211,328
NCT03519945Colitis, Ulcerative · United States, Argentina, Australia and more3Active, not recruitingMar 4, 20261,058
NCT03518086Colitis, Ulcerative · United States, Argentina, Australia and more3CompletedJan 21, 20211,281
NCT03482011Psoriasis · United States, Germany, Japan and more3CompletedMar 21, 2019530
NCT03456713Healthy · United States1CompletedAug 13, 201872
NCT03220126Healthy · United Kingdom1CompletedFeb 23, 201872
NCT03188510Healthy · United States1CompletedNov 27, 201754
NCT03053622Healthy · United Kingdom1CompletedApr 3, 201867
NCT02899988Plaque Psoriasis · United States, Canada, Germany and more2CompletedJun 19, 2017205
NCT02891226Crohn Disease · United States, Australia, Belgium and more2CompletedDec 11, 2018191
NCT02589665Colitis, Ulcerative · United States, Australia, Belgium and more2CompletedDec 19, 2017249
NCT02568423Healthy · United States1CompletedJul 16, 201851
NCT01947933Psoriasis · Canada1CompletedFeb 201545

How it is read

Names in the registry

  • “Mirikizumab”, 24 entries
  • “LY3074828”, 6 entries
  • “Mirikizumab IV”, 3 entries
  • “Mirikizumab SC”, 3 entries
  • “Mirikizumab - SC”, 3 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.